{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:53:11Z","timestamp":1787730791531,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04418-0","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:10:43Z","timestamp":1739765443000},"page":"2415-2423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24)"],"prefix":"10.1007","volume":"57","author":[{"given":"Vincenzo","family":"Iossa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonopane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pontel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Imperatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"4418_CR1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Cancer. Statistic review (http:\/\/seer.cancer.gov\/)."},{"key":"4418_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","volume":"55","author":"M Brake","year":"2000","unstructured":"Brake M, Leortzer H, Horsch R, Keller H (2000) Long-term results of intravesical BCG therapy for stage T1 superficial bladder cancer. Urology 55:673\u2013677","journal-title":"Urology"},{"key":"4418_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF02201977","volume":"15","author":"WH Herr","year":"1997","unstructured":"Herr WH (1997) Natural history of superficial bladders tumors: 10\u201320 years follow-up of treated patients. World J Urol 15:84\u201388","journal-title":"World J Urol"},{"issue":"3","key":"4418_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000315492","volume":"85","author":"M Racioppi","year":"2010","unstructured":"Racioppi M, Volpe A, Cappa E, D\u2019Agostino D, Pinto F, D\u2019Addessi A, Sacco E, Bassi P (2010) Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach. Urol Int 85(3):266\u2013269","journal-title":"Urol Int"},{"key":"4418_CR5","unstructured":"European Association of Urology. Guidelines. 2022"},{"key":"4418_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/BLC-180191","volume":"4","author":"JJ de Jong","year":"2018","unstructured":"de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL (2018) Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer 4:395\u2013401","journal-title":"Bladder Cancer"},{"key":"4418_CR7","doi-asserted-by":"publisher","first-page":"e1150","DOI":"10.1016\/S1569-9056(17)30717-0","volume":"16","author":"WS Tan","year":"2017","unstructured":"Tan WS, Palou J, Kelly J (2017) Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: An interim analysis of 307 patients. Eur Urol Suppl 16:e1150","journal-title":"Eur Urol Suppl"},{"key":"4418_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJM Lammers","year":"2011","unstructured":"Lammers RJM et al (2011) The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 60:81\u201393","journal-title":"Eur Urol"},{"key":"4418_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D (2011) Long-term outcomes of a randomized controlled trial comparing thermo-chemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107:912\u2013918","journal-title":"BJU Int"},{"key":"4418_CR10","first-page":"4721s","volume":"44","author":"CW Song","year":"1984","unstructured":"Song CW (1984) Eect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44:4721s\u20134730s","journal-title":"Cancer Res"},{"key":"4418_CR11","first-page":"1096","volume":"41","author":"BA Teicher","year":"1981","unstructured":"Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC (1981) Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin c toward hypoxic tumor cells. Cancer Res 41:1096\u20131099","journal-title":"Cancer Res"},{"key":"4418_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/028418699432554","volume":"38","author":"O Dahl","year":"1999","unstructured":"Dahl O, Dalene R, Schem BC, Mella O (1999) Status of clinical hyperthermia. Acta Oncol 38:863\u2013873","journal-title":"Acta Oncol"},{"key":"4418_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/00006123-199804000-00092","volume":"42","author":"T Fuse","year":"1998","unstructured":"Fuse T, Yoon K, Kato T, Yamada K (1998) Heat-induced apoptosis in human glioblastoma cell line A172. Neurosurgery 42:843\u2013849","journal-title":"Neurosurgery"},{"key":"4418_CR14","doi-asserted-by":"publisher","first-page":"e3248","DOI":"10.1016\/S1569-9056(19)33634-6","volume":"18","author":"F Chiancone","year":"2019","unstructured":"Chiancone F, Carrino M, Fedelini M, Meccariello C, Fedelini P (2019) Intravesical thermo-chemotherapy using the combined antineoplastic thermotherapy bladder recirculation system for BCG-failure patients: A single-center experience. Eur Urol Supp 18:e3248","journal-title":"Eur Urol Supp"},{"key":"4418_CR15","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-220026","author":"WP Tan","year":"2022","unstructured":"Tan WP, Plata Bello A, Garcia Alvarez C, Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, Nzeh C, Manuel de la Morena J, de Torres IGV, Hendricksen K, D\u00edaz Goizueta FJ, Del \u00c1lamo JF, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Gonzalo Rodr\u00edguez VC, Torres JM, Wilby D, Robinson R, Sousa-Escand\u00f3n A, Mata JL, Pontones Moreno JL, Molina FD, Adriazola Semino MA, Stemberger AT, Escudero JC, Redorta JP, Tan WS (2022) A multicenter study of 2-year outcomes following hyperthermia therapy with mitomycin C in treating non-muscle invasive bladder cancer: HIVEC-E. Bladder Cancer. https:\/\/doi.org\/10.3233\/BLC-220026","journal-title":"Bladder Cancer"},{"key":"4418_CR16","first-page":"287","volume":"73","author":"F Chiancone","year":"2020","unstructured":"Chiancone F, Fabiano M, Fedelini M, Meccariello C, Carrino M, Fedelini P (2020) Outcomes and complications of hyperthermic intravesical chemotherapy using mitomycin c or epirubicin for patients with non-muscle-invasive bladder cancer after bacillus calmette-gu\u00e9rin treatment failure. Cent European J Urol 73:287\u2013294","journal-title":"Cent European J Urol"},{"key":"4418_CR17","first-page":"211","volume-title":"Health measurement scales: a practical guide to their development and use","author":"PM Fayers","year":"2005","unstructured":"Fayers PM, Hays RD (2005) Assessing quality of life in clinical trials. In: Streiner DL, Norman GR (eds) Health measurement scales: a practical guide to their development and use, 3rd edn. Oxford University Press, NY, pp 211\u2013238","edition":"3"},{"key":"4418_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283\u20131286","journal-title":"J Urol"},{"key":"4418_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Hendricksen K et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182:1313\u20131317","journal-title":"J Urol"},{"key":"4418_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1590\/s1677-5538.ibju.2018.0249","volume":"45","author":"M Racioppi","year":"2019","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF (2019) Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non-muscle-invasive bladder cancer? Int Braz J Urol 45:315\u2013324","journal-title":"Int Braz J Urol"},{"key":"4418_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MOU.0000000000000769","volume":"30","author":"R Sari Motlagh","year":"2020","unstructured":"Sari Motlagh R, Pradere B, Mori K, Miura N, Abufaraj M, Shariat SF (2020) Bladder-preserving strategies for Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? Curr Opin Urol 30:584\u2013593","journal-title":"Curr Opin Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04418-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:48:36Z","timestamp":1757137716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04418-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04418-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Was waived by the local Ethics Committee and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all subjects to use their data and information for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}